Risk-benefit profiles of women using tamoxifen for chemoprevention

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Nichols, Hazel B ^a   DeRoo, Lisa A ^b   Scharf, Daniel R ^c   Sandler, Dale P ^d  

^a IL   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c WESTAT   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CAUCASIAN; COHORT ANALYSIS; DRUG USE; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; OVARIECTOMY; PRIMARY PREVENTION; PRIORITY JOURNAL; PUERTO RICAN; RACE DIFFERENCE; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; TELEPHONE INTERVIEW; TREATMENT DURATION; BREAST NEOPLASMS; CHEMOPROPHYLAXIS; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; ODDS RATIO; PROCEDURES; PUERTO RICO; RISK ASSESSMENT; STATISTICAL MODEL; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOPREVENTION; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; PRIMARY PREVENTION; PUERTO RICO; RALOXIFENE HYDROCHLORIDE; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; UNITED STATES;

EID: 84930387437     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju354     Document Type: Article

References (40)

1. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95(7):526-532.
2. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827-1834.
3. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336):817-824.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388.
5. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352(9122):98-101.
6. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352(9122):93-97.
7. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(23):2942-2962.
8. Moyer VA. Medications for Risk Reduction of Primary Breast Cancer in Women: U. S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2013;159(10):698-708.
9. Waters EA, McNeel TS, Stevens WM, et al. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 2012;134(2):875-880.
10. Bastian LA, Lipkus IM, Kuchibhatla MN, et al. Women's interest in chemoprevention for breast cancer. Arch Intern Med. 2001;161(13):1639-1644.
11. Tjia J, Micco E, Armstrong K. Interest in breast cancer chemoprevention among older women. Breast Cancer Res Treat. 2008;108(3):435-453.
12. McKay A, Martin W, Latosinsky S. How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide. Breast Cancer Res Treat. 2005;94(2):153-159.
13. Tchou J, Hou N, Rademaker A, et al. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer. 2004;100(9):1800-1806.
14. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541-1548.
15. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
16. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91(21):1829-1846.
17. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007;99(23):1782-1792.
18. Matsuno RK, Costantino JP, Ziegler RG, et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst. 2011;103(12):951-961.
19. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358-366.
20. Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol. 2011;29(17):2327-2333.
21. Breast Cancer Risk Reduction Guidelines Version 1.2012 National Comprehensive Cancer Center Network. Available at: www.nccn.org. Accessed July 24, 2014.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J. 1958;53:457-480.
23. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381-2391.
24. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBISII): an international, double-blind, randomised placebo-controlled trial. Lancet. 2013;383(9922):1041-1048.
25. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and metaanalysis. J Clin Oncol. 2010;28(18):3090-3095.
26. Fasching PA, von Minckwitz G, Fischer T, et al. The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs. Breast Cancer Res Treat. 2007;101(1):95-104.
27. Julian-Reynier CM, Bouchard LJ, Evans DG, et al. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer. 2001;92(4):959-968.
28. Melnikow J, Paterniti D, Azari R, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer. 2005;103(10):1996-2005.
29. Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res. 2011;4(9):1360-1365.
30. Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat. 2013;138(1):325-328.
31. Chlebowski RT, Kim J, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila). 2014;7(4):378-387.
32. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251-2256.
33. Maurice A, Howell A, Evans DG, et al. Predicting compliance in a breast cancer prevention trial. Breast J. 2006;12(5):446-450.
34. Land SR, Cronin WM, Wickerham DL, et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res. 2011;4(9):1393-1400.
35. Barisic A, Glendon G, Weerasooriya N, et al. Accuracy of Self-Reported Breast Cancer Information among Women from the Ontario Site of the Breast Cancer Family Registry. J Cancer Epidemiol. 2012;2012:310804.
36. Phillips KA, Milne RL, Buys S, et al. Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. J Clin Oncol. 2005;23(21):4679-4686.
37. Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod. 2005;20(6):1511-1515.
38. Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet. 2011;378(9788):338-346.
39. Amrollahi Z, Rezaei F, Salehi B, et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Dis. 2011;129(1-3):327-331.
40. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. New Engl J Med. 2006;355(2):125-137.